Dalpiciclib in advanced breast cancer: introducing CDK4/6 inhibitors as a first-line treatment might not be the best strategy

被引：4
|
作者：
Xu, Binghe [1 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Natl Clin Res Ctr Canc, Beijing 100021, Peoples R China
来源：
LANCET ONCOLOGY | 2023年 / 24卷 / 09期
关键词：
D O I：
10.1016/S1470-2045(23)00361-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E357 / E357
页数：1
相关论文
共 50 条
  • [1] Evaluation of CDK4/6 inhibitors in first-line in symptomatic and asymptomatic patients with metastatic breast cancer
    Oner, Irem
    Turkel, Alper
    Anik, Hicran
    Arslan, Ulku Yalcintas
    Karacin, Cengiz
    FUTURE ONCOLOGY, 2024,
  • [2] Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer
    Marie-Laure Tanguy
    Luc Cabel
    Fréderique Berger
    Jean-Yves Pierga
    Alexia Savignoni
    Francois-Clement Bidard
    npj Breast Cancer, 4
  • [3] Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer
    Tanguy, Marie-Laure
    Cabel, Luc
    Berger, Frederique
    Pierga, Jean-Yves
    Savignoni, Alexia
    Bidard, Francois-Clement
    NPJ BREAST CANCER, 2018, 4
  • [4] Overall survival in first-line HRD/HER2-advanced breast cancer in the era of CDK4/6 inhibitors
    Sanchez-Bayona, Rodrigo
    Oliveira, Mafalda
    ANNALS OF ONCOLOGY, 2024, 35 (08) : 689 - 691
  • [5] Incorporating CDK4/6 Inhibitors in the Treatment of Advanced Luminal Breast Cancer
    Echavarria, Isabel
    Jerez, Yolanda
    Martin, Miguel
    Lopez-Tarruella, Sara
    BREAST CARE, 2017, 12 (05) : 296 - 302
  • [6] Longer Overall Survival with CDK-4/6 Inhibitors in First-line advanced Breast Cancer
    Klein, Friederike
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (06) : 560 - 560
  • [7] Confirming the efficacy and safety of CDK4/6 inhibitors in the first-line treatment of HR plus advanced breast cancer: a systematic review and meta-analysis
    Guan, Xin
    Li, Mengyuan
    Ji, Xinyue
    Wang, Yufei
    Tian, Lei
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [8] Evolving treatment paradigms after CDK4/6 inhibitors in advanced breast cancer
    Gnant, Michael
    Balic, Marija
    Singer, Christian F.
    Rinnerthaler, Gabriel
    Pfeiler, Georg
    Suppan, Christoph
    Gruenberger, Birgit
    Strasser-Weippl, Kathrin
    Castagnaviz, Vanessa
    Heibl, Sonja
    Bartsch, Rupert
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2025, 18 (01) : 4 - 18
  • [9] CDK4/6 Inhibitors in the Treatment of Metastatic Breast Cancer
    Ettl, Johannes
    Huober, Jens
    Lueftner, Diana
    Marme, Frederik
    Wuerstlein, Rachel
    BREAST CARE, 2017, 12 (02) : 118 - 120
  • [10] Breast cancer management with CDK4/6 inhibitors as first line treatment: a single institution retrospective review
    Villa, F.
    Corbetta, C.
    Crippa, A.
    Pelizzoni, D.
    Vittimberga, I.
    Sansi, C.
    Arnoffi, J.
    Guida, F. M.
    Cuomo, O.
    Tafuni, M.
    Sassone, M. C.
    Vigano, C. V.
    Anghilieri, M.
    Ardizzoia, A.
    EUROPEAN JOURNAL OF CANCER, 2022, 175 : S69 - S70
12345